Latest On Galapagos NV (GLPGF):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-05 21:33 EST | News | Galapagos NV (GLPG) Q1 2023 Earnings Call Transcript | N/A |  |
| 2023-05-03 05:22 EST | News | Galapagos announces departure of COO and CFO Bart Filius | N/A | |
| 2023-02-24 11:44 EST | News | Galapagos NV (GLPG) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-02-11 10:17 EST | News | Galapagos: Crohn's Disease Trial Failure, Still Maintaining A Buy Rating | N/A | |
| 2022-11-07 11:36 EST | News | Galapagos downgraded to market perform at Raymond James on unclear path forward | N/A | |
| 2022-10-03 19:33 EST | News | EMA panel approves amending label for Galapagos' Jyseleca on testicular function effects | N/A | |
| 2022-08-29 22:04 EST | News | Galapagos receives transparency notification from FMR | N/A | |
| 2022-08-06 18:31 EST | News | Galapagos NV (GLPG) CEO Paul Stoffels on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-05-06 13:51 EST | News | Galapagos NV (GLPG) CEO Paul Stoffels on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-05-06 13:51 EST | News | Galapagos NV 2022 Q1 - Results - Earnings Call Presentation | N/A | |
| 2022-02-25 18:32 EST | News | Galapagos NV (GLPG) CEO Onno van de Stolpe on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-02-25 01:13 EST | News | Galapagos GAAP EPS of -€1.58, revenue of €484.85M | N/A | |
| 2021-11-05 17:37 EST | News | Galapagos NV's (GLPG) CEO Onno van de Stolpe on Q3 2021 Results - Earnings Call Transcript | N/A | |
| 2021-08-08 04:55 EST | News | Galapagos NV (GLPG) CEO Onno van de Stolpe on Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-03-19 06:58 EST | News | Galapagos (GLPG) Investor Presentation - Slideshow | N/A | |
| 2021-02-22 05:16 EST | Financials | Company financials have been released. | Neutral | |
| 2021-02-21 05:05 EST | Financials | Company financials have been released. | Neutral | |
| 2021-02-20 12:23 EST | News | Galapagos NV's (GLPG) CEO Onno van de Stolpe on Q4 2020 Results - Earnings Call Transcript | N/A | |
| 2020-12-30 17:14 EST | News | Galapagos: Market Values Pipeline Below $0 | N/A | |
| 2020-11-26 22:51 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-14 06:22 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-08 01:53 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 21:52 EST | News | Galapagos NV 2020 Q3 - Results - Earnings Call Presentation | N/A | |
| 2020-11-07 21:52 EST | News | Galapagos NV (GLPG) CEO Onno van de Stolpe on Q3 2020 Results - Earnings Call Transcript | N/A | |
| 2020-11-07 18:15 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-26 15:08 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-26 10:00 EST | News | Galapagos ADR (GLPG) Investor Presentation - Slideshow | N/A | |
| 2020-09-17 07:15 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 11:10 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-09 02:25 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-08 07:36 EST | News | Galapagos NV's (GLPG) CEO Onno van de Stolpe on Q2 2020 Results - Earnings Call Transcript | N/A | |
| 2020-08-08 02:29 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 14:45 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 10:30 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 18:54 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 06:53 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-29 23:05 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 14:46 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 19:33 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 10:58 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 18:42 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 02:28 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-19 14:35 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-14 06:41 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-12 08:17 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-27 07:18 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-21 23:10 EST | News | Gilead And Galapagos: Filgotinib Ulcerative Colitis Trial Review | N/A | |
| 2020-05-21 02:52 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-11 22:27 EST | News | Galapagos NV (GLPG) CEO Onno van de Stolpe on Q1 2020 Results - Earnings Call Transcript | N/A | |
| 2020-05-10 02:36 EST | Financials | Company financials have been released. | Neutral | |
About Galapagos NV (GLPGF):
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, Sjögren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company's clinical stage programs also comprise GLPG1690, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof-of-concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, it engages in the development of GLPG1972, which is in the ROCCELLA Phase 2b trial for treating osteoarthritis; and Toledo molecules, including GLPG3312, GLPG3970, and GLPG4399 for inflammation. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; Novartis Pharma AG; Les Laboratoires Servier and Institut de Recherches Servier; and Ryvu Therapeutics S.A. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.
General
- Name Galapagos NV
- Symbol GLPGF
- Type Common Stock
- Exchange OTCGREY
- Currency USD
- Country USA
- Fiscal Year EndDecember
- Web URLhttp://www.glpg.com
View More
Financials
- Most Recent Quarter 2020-09-30
- Profit Margin -58%
- Return on Assets -2%
- Return on Equity -11%
- Earnings Per Share -$1.69
- Revenue Per Share $0
- Gross Profit 6.6 million
- Quarterly Earnings Growth -77.6%
View More
Highlights
- Market Capitalization 4.45 billion
- Analyst Target Price $66.05
- Book Value Per Share $25.49
View More
Share Statistics
- Shares Outstanding 54.3 million
- Shares Float 43.14 million
- % Held by Insiders 2627%
- % Held by Institutions 35.28%
View More
Technicals
- Beta 0.28
- 52 Week High $223
- 52 Week Low $81
- 50 Day Moving Average 90.75
- 200 Day Moving Average 114.04
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Galapagos NV (GLPGF) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Galapagos NV (GLPGF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-06-30 | 2020-09-30 | $N/A | -$1.47 | $0.00 | |
| 2020-03-31 | 2020-06-30 | $N/A | -$1.99 | -$0.42 | -373.57% |
| 2019-12-31 | 2020-03-31 | $143.43 million | -$0.86 | -$0.26 | -230.88% |
| 2019-09-30 | 2019-12-31 | $643.95 million | -$2.04 | -$0.52 | -291.79% |
| 2019-06-30 | 2019-09-30 | $67.59 million | $6.57 | -$1.13 | 681.67% |
| 2019-03-31 | 2019-06-30 | $40.92 million | -$0.98 | -$0.97 | -1.03% |
| 2018-12-31 | 2019-03-31 | $112.77 million | -$1.00 | -$0.60 | -66.55% |
| 2018-09-30 | 2018-12-31 | $80.56 million | $0.32 | -$0.62 | 150.97% |
| 2018-06-30 | 2018-09-30 | $66.38 million | $0.33 | -$0.58 | 156.05% |
| 2018-03-31 | 2018-06-30 | $55.16 million | -$0.50 | -$0.96 | 48.42% |
| 2017-12-31 | 2018-03-31 | $59.52 million | -$0.90 | -$0.06 | -1394% |
| 2017-09-30 | 2017-12-31 | $33.32 million | -$0.71 | -$0.72 | 1.71% |
| 2017-06-30 | 2017-09-30 | $33.17 million | -$0.86 | -$0.59 | -46.24% |
| 2017-03-31 | 2017-06-30 | $39.86 million | -$0.81 | -$0.58 | -39.83% |
| 2016-12-31 | 2017-03-31 | $86.57 million | -$0.31 | $0.00 | |
| 2016-09-30 | 2016-12-31 | $1.01 | $0.00 | ||
| 2016-06-30 | 2016-09-30 | -$0.59 | -$0.13 | -352.62% | |
| 2016-03-31 | 2016-06-30 | -$0.09 | $0.10 | -189.8% | |
| 2015-12-31 | 2016-03-31 | $0.90 | -$0.85 | 205.85% | |
| 2015-09-30 | 2015-12-31 | -$1.58 | -$0.71 | -123.21% | |
| 2015-06-30 | 2015-09-30 | -$0.78 | $0.00 | ||
| 2015-03-31 | 2015-06-30 | -$0.65 | $0.00 | ||
| 2014-12-31 | 2015-03-31 | -$0.50 | $0.00 | ||
| 2014-09-30 | 2014-12-31 | -$0.42 | $0.00 | ||
| 2014-06-30 | 2014-09-30 | -$0.51 | $0.00 | ||
| 2014-03-31 | 2014-06-30 | -$0.33 | $0.00 | ||
| 2013-12-31 | 2014-03-31 | -$0.34 | $0.00 | ||
| 2013-03-31 | 2013-06-30 | -$0.14 | $0.00 | ||
| 2012-12-31 | 2013-03-31 | $121.59 million | -$0.14 | $0.00 | |
| 2012-06-30 | 2012-09-30 | $0.13 | $0.00 | ||
| 2012-03-31 | 2012-06-30 | -$0.27 | $0.00 | ||
| 2011-12-31 | 2012-03-31 | -$0.29 | $0.00 | ||
| 2011-09-30 | 2011-12-31 | -$0.06 | $0.00 | ||
| 2011-06-30 | 2011-09-30 | -$0.06 | $0.00 | ||
| 2011-03-31 | 2011-06-30 | -$0.77 | $0.00 | ||
| 2010-12-31 | 2011-03-31 | -$0.75 | $0.00 | ||
| 2010-09-30 | 2010-12-31 | $0.30 | $0.00 |
Galapagos NV (GLPGF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | N/A | N/A | N/A |
| Income Before Tax | N/A | N/A | N/A | -98.57 million | 344.41 million |
| Selling General Administrative | N/A | N/A | N/A | 37.08 million | 32.64 million |
| Gross Profit | N/A | N/A | N/A | 14.35 million | 523.27 million |
| Ebit | N/A | N/A | N/A | -22.73 million | 490.63 million |
| Operating Income | N/A | N/A | N/A | -22.73 million | 490.63 million |
| Income Tax Expense | 387000 | 364000 | 300000 | 16.91 million | -16.83 million |
| Total Revenue | N/A | N/A | N/A | 143.43 million | 643.95 million |
| Cost of Revenue | N/A | N/A | N/A | 129.07 million | 120.68 million |
| Total Other Income Expense Net | N/A | N/A | N/A | -75.84 million | -146.23 million |
| Net Income From Continuing Operations | N/A | N/A | N/A | -115.48 million | 361.23 million |
| Net Income Applicable to Common Shares | -81.91 million | -115 million | -50.6 million | -115.48 million | 361.23 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | N/A | -3.72 billion | N/A |
| Change to Liabilities | -75.06 million | -82.53 million | N/A | -155.35 million | 3 billion |
| Total Cash Flow from Investing Activities | -81.08 million | -216.84 million | N/A | -3.74 billion | -14.22 million |
| Net Borrowings | -2.05 million | -1.6 million | N/A | -1.26 million | -1.69 million |
| Total Cash Flow from Financial Activities | N/A | N/A | N/A | 365.02 million | 965.07 million |
| Change to Operating Activities | 11.57 million | N/A | N/A | 12.7 million | 1000 |
| Change in Cash | N/A | N/A | N/A | -3.74 billion | 4.45 billion |
| Total Cash from Operating Activities | -180.34 million | -140.96 million | N/A | -120.14 million | 3.47 billion |
| Depreciation | N/A | N/A | N/A | -8.84 million | 3.18 million |
| Other Cash Flow from Investing Activities | 187000 | 699000 | N/A | 5.06 million | N/A |
| Change to Inventory | N/A | N/A | N/A | -3000 | N/A |
| Change to Account Receivables | N/A | N/A | N/A | 28.14 million | 4.75 million |
| Other Cash Flow from Financing Activities | -1000 | 1000 | N/A | -4.45 million | N/A |
| Change to Net Income | 68.87 million | 60.31 million | N/A | 118.69 million | 105.27 million |
| Capital Expenditures | N/A | N/A | N/A | 5.06 million | 12.29 million |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | N/A | N/A | N/A | 3.19 billion |
| Total Stockholder Equity | N/A | N/A | N/A | N/A | 2.88 billion |
| Other Current Liabilities | N/A | 437.37 million | N/A | N/A | 422.53 million |
| Total Assets | N/A | N/A | N/A | N/A | 6.07 billion |
| Common Stock | N/A | 290.93 million | 290.46 million | N/A | 287.28 million |
| Other Current Assets | N/A | 15.87 million | N/A | N/A | 9.14 million |
| Retained Earnings | N/A | -297.1 million | -235.22 million | N/A | -109.22 million |
| Other Liabilities | N/A | 2.39 billion | 2.44 billion | N/A | 2.6 billion |
| Other Assets | N/A | 121.54 million | 116.52 million | N/A | 111.7 million |
| Cash | N/A | N/A | N/A | N/A | 1.86 billion |
| Total Current Liabilities | N/A | 601.74 million | N/A | N/A | 571.79 million |
| Other Stockholder Equity | N/A | -7.36 million | -5.65 million | N/A | -5.98 million |
| Property, Plant & Equipment | N/A | 94.66 million | 73.79 million | N/A | 66.05 million |
| Total Current Assets | N/A | 5.46 billion | N/A | N/A | 5.87 billion |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | 2.67 billion | 2.67 billion | 2.73 billion | 2.87 billion | 2.85 billion |
| Short Term Investments | N/A | N/A | N/A | N/A | 3.92 billion |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | 157.26 million | N/A | N/A | 143.43 million |
Galapagos NV (GLPGF) Chart:
Galapagos NV (GLPGF) News:
Below you will find a list of latest news for Galapagos NV (GLPGF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Galapagos NV (GLPGF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Galapagos NV (GLPGF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|